TRASTUZUMAB INDUCED CARDIOTOXICITY IN PATIENTS WITH HER2+BREAST CANCER

被引：0
|
作者：
Santamaria Elena, Capilla [1 ]
Garcia Beatriz, Benitez [1 ]
Jose Antonio, Romero Garrido [1 ]
Aunon Pilar, Zamora [2 ]
Abad Gema, Casado [1 ]
del Valle Luis, Gonzalez [1 ]
Ambrosio Alicia, Herrero [1 ]
机构：
[1] Hosp Univ La Paz, Dept Pharm, Madrid, Spain
[2] Hosp Univ La Paz, Dept Oncol, Madrid, Spain
来源：
ATENCION FARMACEUTICA | 2013年 / 15卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Objective: To assess the incidence of trastuzumab induced cardiotoxicity in clinical practice. Method: A retrospective study was conducted on HER2+ breast cancer patients who started treatment with trastuzumab in 2008 and 2009, and were monitored for one year. Results: 67 patients were included. The cardiotoxicity incidence was 46.3% with a mean time of onset from 5.5 +/- 3.3 months. The most commonly criterion was the decline in LVEF (Left Ventricular Ejection Fraction) >10 points from baseline value (28.4%). 45.1% of the cases were symptomatic cardiotoxicity. A baseline LVEF of >67% was associated with cardiotoxicity (p < 0.05). Conclusions: The incidence of cardiotoxicity in clinical practice was higher than that obtained in different clinical trials. It is necessary to reach consensus between professionals to ensure the drug's safety without limiting benefit for the patient.
引用
收藏
页码：261 / 267
页数：7
相关论文
共 50 条
  • [41] STAT6 expression and trastuzumab resistance in HER2+breast cancer.
    Cobleigh, Melody A.
    DiScala, Molly
    Najor, Matthew S.
    Yung, Timothy
    Abukhdeir, Abde M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] Targeting trastuzumab-resistant HER2+breast cancer with a HER3-targeting nanoparticle
    Sims, Jessica
    Taguaim, Michael
    Hanson, Chris
    Cui, Xiaojiang
    Medina-Kauwe, Lali K.
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [43] Visualizing trastuzumab-deruxtecan action in HER2+breast cancer cells at nanoscale
    Cortese, K.
    Garrone, O.
    Gagliani, M. C.
    Bellese, G.
    Arnaldi, P.
    Abbona, A.
    Paccagnella, M.
    Ruatta, F.
    Merlano, M. C.
    Castagnola, P.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S197 - S197
  • [44] Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer
    Vaynrub, Anna
    Mishalani, Leila
    Raikhelkar, Jayant
    Crew, Katherine D.
    [J]. CARDIO-ONCOLOGY, 2024, 10 (01)
  • [45] Evaluation of Cardiotoxicity in HER-2 Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab
    Bachir, B.
    Anouti, S.
    Jaoude, J. Abi
    Kayali, M.
    Tfayli, A.
    De Azambuja, E.
    Poortmans, P.
    Zeidan, Y.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S7 - S7
  • [46] Trastuzumab sensitizes HER2+breast cancer to increase efficacy of chemotherapy in vitro and in vivo
    Shah, Alay
    Jarrett, Angela
    Syed, Anum
    Yankeelov, Thomas
    Sorace, Anna
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [47] Evaluation of Cardiotoxicity in HER-2-Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab
    Bachir, Bachir
    Anouti, Sirine
    Jaoude, Joseph Abi
    Kayali, Majd
    Tfayli, Arafat
    de Azambuja, Evandro
    Poortmans, Philip
    Zeidan, Youssef H.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 113 (01): : 135 - 142
  • [48] Mathematical modelling of trastuzumab-induced immune response in an in vivo murine model of HER2+breast cancer
    Jarrett, Angela M.
    Bloom, Meghan J.
    Godfrey, Wesley
    Syed, Anum K.
    Ekrut, David A.
    Ehrlich, Lauren I.
    Yankeelov, Thomas E.
    Sorace, Anna G.
    [J]. MATHEMATICAL MEDICINE AND BIOLOGY-A JOURNAL OF THE IMA, 2019, 36 (03): : 381 - 410
  • [49] Investigating trastuzumab-induced myeloid cell alterations for improving combination therapy in HER2+breast cancer
    Bloom, M. J.
    Jarrett, A. M.
    Triplett, T. A.
    Syed, A. K.
    Yankeelov, T. E.
    Sorace, A. G.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [50] Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+breast cancer
    Dackus, Gwen M. H. E.
    Jozwiak, Katarzyna
    van der Wall, Elsken
    van Diest, Paul J.
    Hauptmann, Michael
    Siesling, Sabine
    Sonke, Gabe S.
    Linn, Sabine C.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (03) : 817 - 830
12345